Overactive bladder: the importance of new guidance
- 8 September 2006
- journal article
- review article
- Published by Hindawi Limited in International Journal Of Clinical Practice
- Vol. 60 (10) , 1263-1271
Abstract
Overactive bladder (OAB) affects an estimated 49 million people in Europe, but only a minority receive appropriate treatment. Others are bothered by unacceptable levels of symptoms that severely impair their quality of life and represent a significant financial burden to themselves and to their healthcare providers. Recently updated guidelines from the International Consultation on Incontinence (ICI) and the European Association of Urology (EAU) take account of important new developments in the management of bladder problems in both primary and secondary care. However, local implementation of previous guidance has been variable, with many patients with OAB and other bladder problems failing to gain full benefit from current clinical and scientific understanding of these conditions. The recent expansion of the range of treatments available for OAB and stress urinary incontinence makes it especially important that physicians become aware of the differential diagnosis of these conditions – the questions they need to ask, and the investigations which will help determine the most appropriate course of action.Keywords
This publication has 14 references indexed in Scilit:
- Urinary incontinence in the elderly: Attitudes and experiences of general practitionersScandinavian Journal of Primary Health Care, 2006
- A Comparison of the Efficacy and Tolerability of Solifenacin Succinate and Extended Release Tolterodine at Treating Overactive Bladder Syndrome: Results of the STAR TrialEuropean Urology, 2005
- Health‐related consequences of overactive bladder: an economic perspectiveBJU International, 2005
- 232Comparative safety and tolerability of antimuscarinic treatments for overactive bladder: Results of a systematic reviewEuropean Urology Supplements, 2005
- PUK11 PATIENT PERSISTENCY WITH MEDICATIONS FOR OVERACTIVE BLADDERValue in Health, 2004
- The cost of clinically significant urinary storage symptoms for community dwelling adults in the UKBJU International, 2004
- Randomized, double‐blind placebo‐ and tolterodine‐controlled trial of the once‐daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladderBJU International, 2004
- The standardisation of terminology of lower urinary tract function: Report from the standardisation sub‐committee of the International Continence SocietyNeurourology and Urodynamics, 2002
- A medium term analysis of the subjective efficacy of treatment for women with detrusor instability and low bladder complianceBJOG: An International Journal of Obstetrics & Gynaecology, 1997
- The Quality of Life in Women with Urinary Incontinence as Measured by the Sickness Impact ProfileJournal of the American Geriatrics Society, 1991